Last checked at 22 Feb 2016 13:39
22 FEBRUARY 2016
ImmuPharma PLC
Result of GM
ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce that at its General Meeting today, held in connection with the Placing and Subscription, as announced on 5 February 2016, all resolutions were duly passed.
Commenting on the announcement, Tim McCarthy, Chairman of ImmuPharma, said: "We are delighted to have received such support from our existing shareholders and new investors in this placing to fund our pivotal Phase III Lupuzor™ trial. Having recently announced that we have commenced dosing our first Lupus patients in the US, we look forward to providing regular updates on the trial through this year and 2017."
For further information please see the Company's website, www.immupharma.org, or contact:
ImmuPharma plc Tim McCarthy, Chairman Lisa Baderoon, Head of Investor Relations
| + 44 (0) 20 7152 4080
+ 44 (0) 7721 413496 lisa.baderoon@immupharma.com |
Panmure Gordon (Financial Adviser, Nominated Adviser & Broker) Fred Walsh, Duncan Monteith, Corporate Finance Charles Leigh-Pemberton, Corporate Broking
| +44 (0) 20 7886 2500 |
All defined terms used in this announcement are defined, unless otherwise defined here, in the appendix to the Proposed Placing and Subscription and Notice of General Meeting announcement made on 5 February 2016.